Advanced Non Small Cell Lung Cancer Clinical Trial
Official title:
Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).
Pre-clinical studies support the proposed dosing schema to be tested and a potential benefit of the combination of inhaled DV281 with nivolumab for subjects with advanced NSCLC. This study (DV9-NSC-01) is designed for establishing an immunologically optimal RP2D for inhaled DV281 in combination with an approved anti-PD-1 inhibitor. This trial, studying the potential to enhance the efficacy of an approved anti-PD-1 inhibitor in subjects with advanced NSCLC, addresses an unmet need for NSCLC patients having tumors that do not respond or do not respond adequately to anti-PD-1 inhibitor monotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02157883 -
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
|
Phase 1 | |
| Completed |
NCT00072631 -
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02163733 -
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06107374 -
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
|
Phase 2 | |
| Completed |
NCT01802632 -
AZD9291 First Time In Patients Ascending Dose Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06406166 -
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
|
N/A | |
| Terminated |
NCT04785365 -
Long-Term Follow-Up Study of Patients Receiving ATL001
|
Phase 2 | |
| Recruiting |
NCT04032847 -
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT01631136 -
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04239443 -
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
|
Phase 2 | |
| Completed |
NCT03452150 -
D-0316 First Time in Patients Ascending Dose Study
|
Phase 1 | |
| Completed |
NCT04144608 -
Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04755738 -
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652857 -
Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03351361 -
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
|
Phase 3 | |
| Completed |
NCT02407327 -
Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
|
||
| Active, not recruiting |
NCT02143466 -
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
|
Phase 1 | |
| Recruiting |
NCT05004974 -
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05777603 -
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT04886401 -
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC
|